Meet the Adjuvance Management Team

Tyler Martin, M.D.

Chief Executive Officer and Chairman

Dr. Tyler Martin is the Chairman and CEO of Adjuvance Technologies. Prior to Adjuvance, Dr. Martin held senior leadership positions in a number of biotech companies including Chiron, Sangamo, and Dynavax Technologies. Dr. Martin has led teams that filed more than 100 Investigational New Drug (IND) Applications including two adjuvanted vaccines approved by major regulatory authorities, Fluad and Heplisav-B. Dr. Martin received his M.D. from the University of Nebraska, College of Medicine, and served as a Resident in Pediatrics at the University of Nebraska Medical Center.

Sean Bennett, M.D., Ph.D.

Chief Medical Officer

Sean Bennett, M.D., Ph.D., joined the Adjuvance Team as Chief Medical Officer in April 2020. He brings 16 years of clinical development experience, including safety assessment of novel vaccine adjuvants. Dr. Bennett has contributed to the licensure of multiple novel vaccines and anti-infectives and has worked to advance immunotherapeutics, as well. Prior to joining Adjuvance, he led clinical development at PaxVax (subsequently acquired by Emergent BioSolutions), served as Principal at HGB Consulting Limited, and was Senior Medical Director at Aimmune Therapeutics. Dr. Bennett earned his M.D. and Ph.D. (Immunology) from the University of Colorado and trained in pediatrics at Dartmouth.

Pat Frenchick, Ph.D.

Chief Scientific Officer

Patrick (Pat) Frenchick joined Adjuvance as Chief Scientific Officer in April 2020. Dr. Frenchick has more than 30 years of experience in the development of new therapeutic technologies, from discovery through the initiation of clinical trials. His focus has been vaccines, adjuvants, and formulations, including work with saponins, MPL, cytokines, other chemical adjuvants, and formulations to reduce side effects and access optional routes of vaccine delivery. He has also worked in senior positions in the acquisition of technologies, strategic planning, and portfolio management in the US and in Europe. In his career, Dr. Frenchik has held positions as Senior VP Research and Development at Clear Path vaccines, VP Operations and Clinical Operations CytImmune Sciences, and VP Development Combinature Biopharma. Dr. Frenchick received his B.S. in Biochemistry and Ph.D. in Immunology from the University of Minnesota, was an NIH Postdoctoral Fellow in Virology at Baylor College of Medicine and has an MBA from Queen’s University (Kingston, ON, Canada). He is also a US Patent Agent.

Stephan Schulze, MBA 

Chief Financial Officer

Stephan Schulze joined Adjuvance Technologies as its Chief Financial Officer in 2019. Mr. Schulze has more than 27 years of experience in finance and management, having previously worked in various finance roles at Eli Lilly and Company, CFO of Ceva US Holdings, Inc., and Continental Disc Corporation. He also spent time working for different affiliates of Boehringer Ingelheim as Director of Finance, Director Marketing & Sales Controlling, and, finally, as Director of Operations Controlling. During that time he was in charge of the financial integration of the acquired Fort Dodge Animal Health business. His educational background includes a Diplom-Betriebswirt (BA) from Verwaltungs-und Wirtschaftsakademie, Stuttgart, and a Master of Business Administration from Vanderbilt University.

Melissa Malhame, MBA

Vice President, Business Development

Melissa Malhame joined in December 2020 as the Vice President of Business Development. She brings more than 20 years of global vaccine experience spanning the private and public sectors. Ms. Malhame has supported the World Health Organization, the Wellcome Trust, the Coalitions for Epidemic Preparedness Innovation, and the Bill and Melinda Gates Foundation as a consultant. She has also led market shaping efforts for Gavi, The Vaccine Alliance where she was accountable for ensuring the supply of vaccines at affordable prices, for setting long-term access strategies, and for leading Alliance relationships with the vaccine industry. Previously Ms. Malhame led and contributed to business development, strategic planning, and late-stage program leadership focused on a now-licensed novel hepatitis B vaccine at Dynavax Technologies. Melissa joined Dynavax following a decade in progressively senior vaccine marketing and sales roles with Merck. Melissa serves in advisory roles to the RIGHT Fund, the Biotechnology Innovation Organization, PharmaJet Inc., and MedAccess. Melissa has an MBA from Cornell University and BA in International Affairs and Economics from Lafayette College.